WO2009054952A3 - Small molecule inhibitors of parp activity - Google Patents

Small molecule inhibitors of parp activity Download PDF

Info

Publication number
WO2009054952A3
WO2009054952A3 PCT/US2008/011990 US2008011990W WO2009054952A3 WO 2009054952 A3 WO2009054952 A3 WO 2009054952A3 US 2008011990 W US2008011990 W US 2008011990W WO 2009054952 A3 WO2009054952 A3 WO 2009054952A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
molecule inhibitors
parp activity
componds
parp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/011990
Other languages
French (fr)
Other versions
WO2009054952A2 (en
Inventor
Bijoy Panicker
Dawoon Jung
Xiaokang Zhu
David E Smith
Dong Sung Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Priority to AU2008317417A priority Critical patent/AU2008317417A1/en
Priority to EP08843240A priority patent/EP2214667A2/en
Publication of WO2009054952A2 publication Critical patent/WO2009054952A2/en
Publication of WO2009054952A3 publication Critical patent/WO2009054952A3/en
Priority to US12/592,163 priority patent/US20110098304A1/en
Priority to IL205299A priority patent/IL205299A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Componds and pharmaceutical compositions are provided that inhibit the activity of poly ADP-ribose synthetase (PARP). Such componds are useful in the treatment of various diseases, conditions and injuries such as stroke, myocardial infarction, ischemia-perfusion injury in various organs, traumatic brain injury, atherosclerosis, inflammatory diseases and cancer.
PCT/US2008/011990 2007-10-22 2008-10-22 Small molecule inhibitors of parp activity Ceased WO2009054952A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2008317417A AU2008317417A1 (en) 2007-10-22 2008-10-22 Small molecule inhibitors of PARP activity
EP08843240A EP2214667A2 (en) 2007-10-22 2008-10-22 Small molecule inhibitors of parp activity
US12/592,163 US20110098304A1 (en) 2008-10-22 2009-11-19 Small molecule inhibitors of PARP activity
IL205299A IL205299A0 (en) 2007-10-22 2010-04-22 Parp inhibitor compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99991107P 2007-10-22 2007-10-22
US60/999,911 2007-10-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/592,163 Continuation US20110098304A1 (en) 2008-10-22 2009-11-19 Small molecule inhibitors of PARP activity

Publications (2)

Publication Number Publication Date
WO2009054952A2 WO2009054952A2 (en) 2009-04-30
WO2009054952A3 true WO2009054952A3 (en) 2009-08-06

Family

ID=40580286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011990 Ceased WO2009054952A2 (en) 2007-10-22 2008-10-22 Small molecule inhibitors of parp activity

Country Status (4)

Country Link
EP (1) EP2214667A2 (en)
AU (1) AU2008317417A1 (en)
IL (1) IL205299A0 (en)
WO (1) WO2009054952A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584756B2 (en) 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6488239B2 (en) * 2013-01-18 2019-03-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Phthalazinone and isoquinolinone as ROCK inhibitors
MX365950B (en) 2013-03-13 2019-06-19 Flatley Discovery Lab Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis.
US20150320706A1 (en) 2014-05-12 2015-11-12 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CN113226322A (en) * 2018-10-30 2021-08-06 诺维逊生物股份有限公司 Heterocyclic compounds as BET inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183325A1 (en) * 2000-10-30 2002-12-05 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
US20060063767A1 (en) * 2004-08-26 2006-03-23 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6677333B1 (en) * 1999-01-26 2004-01-13 Ono Pharmaceutical Co., Ltd. 2H-phthalazin-1-one derivatives and drug containing its derivatives as active ingredient
US20020183325A1 (en) * 2000-10-30 2002-12-05 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US20060063767A1 (en) * 2004-08-26 2006-03-23 Kudos Pharmaceuticals Ltd Phthalazinone derivatives
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COCKCROFT, X. ET AL.: "Phthalazinones 2: Optimization and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS., vol. 16, no. 4, 2006, pages 1040 - 1044, XP025106435 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584756B2 (en) 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors

Also Published As

Publication number Publication date
EP2214667A2 (en) 2010-08-11
WO2009054952A2 (en) 2009-04-30
IL205299A0 (en) 2010-12-30
AU2008317417A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2011002520A3 (en) Small molecule inhibitors of parp activity
IL191984A0 (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents for the treatment of cancer
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
EP4403216A3 (en) Substituted tricyclic compounds as fgfr inhibitors
IL192763A (en) Pyrimidine derivatives, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of cancer
WO2007059108A3 (en) Substituted quinolones and methods of use
IL185517A (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2011006794A8 (en) 3-oxo-2, 3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
WO2008098104A8 (en) Inhibitors of akt activity
MY157177A (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
UA101493C2 (en) Azetidine and cyclobutane derivatives as jak inhibitors
WO2004080423A3 (en) 7-amino- isoindolyl compounds amd their pharmaceutical uses
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
MX2010004995A (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-î±]imidazole-3- carboxylic acid amides.
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2009158371A8 (en) Inhibitors of akt activity
WO2011006803A8 (en) 3-0x0-2, 3, -dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
CL2008000629A1 (en) MACROCICLICAL COMPOUNDS DERIVED FROM 6-ARIL-4-MERCAPTO- [1.3.5] TRIAZINA / [1.3] PIRIMIDIN-2-AMINA; PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT OF CANCER.
WO2009054952A3 (en) Small molecule inhibitors of parp activity
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
IL199214A (en) Product comprising a combination of pemirolast and a statin, pharmaceutical compositions and kit comprising the same and their use in the treatment of inflammatory disorders
TW200722098A (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in pharmaceutical compositions for treating cancer
MX2011012717A (en) DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLI C ACID AMIDES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843240

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010531022

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008317417

Country of ref document: AU

Ref document number: 1848/KOLNP/2010

Country of ref document: IN

Ref document number: 2008843240

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008317417

Country of ref document: AU

Date of ref document: 20081022

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: JP